Research Partnership appoints new CEO
January 9, 2023 |
Research Partnership has appointed Gareth Phillips to take over as CEO
Research Partnership has appointed Gareth Phillips to take over as CEO, effective 9th January 2023. The two co-founding Directors, Mary Assimakopoulos and Mark Jeffery, are taking a step back from the operational running of the business, although they will remain on the Senior Management Team in an advisory capacity.
Research Partnership was acquired by Inizio last year and sits within the Advisory business unit. Inizio is a strategic partner for health and life sciences that unites a full suite of advisory, medical, marketing, communications, and patient and stakeholder engagement services.
Gareth was previously UK Managing Director and Head of EMEA for Ipsos, one of the world’s leading market research companies. He brings with him a wealth of global experience, having spent 25 years in healthcare market research working with IMS Health (now IQVIA) and Synovate Healthcare before it was acquired by Ipsos. At Synovate, he held roles based in the US, UK and Asia, and was the company’s Managing Director of Asia Pacific at the time of integration into Ipsos. Whilst at Ipsos, he spearheaded a transformation of the healthcare business in Europe, leading them to achieve consistent high growth over the past decade, and growing the team in London to more than 250 people.
Commenting on his appointment, Gareth said, “I am delighted and honoured to be taking on the role as CEO. I have long admired Research Partnership as a leader in the global healthcare market research space and look forward to building on the incredible success that Mark and Mary have achieved in the last 25 years.”
Previous co-Founding Director Mark Jeffery adds, “Gareth is a highly regarded figure in healthcare market research, and with him, we know that the company is in safe hands. We are confident that he will continue the strong growth that the company has enjoyed since its inception in 1997. We wish him every success.”
Gareth will report to Colin Stanley, President of Inizio Advisory.
To find out more about Research Partnership, visit www.researchpartnership.com
To find out more about Inizio and Inizio Advisory, please visit: www.inizio.health
This content was provided by Inizio
Company Details
Latest Content from Inizio
Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.
Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
How DataGateway unified oncology data for real-world insights & market intelligence
Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.
Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement
Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
AI without limits: A smarter, integrated approach to Medical Affairs
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...
What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
AI with intent: How Inizio is redefining pharma through precision and partnership
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...
Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.